Drug Trial Radar · NCT07851103
A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Nov 10, 2026
Primary completion
Sep 3, 2030
Study completion Sep 3, 2030
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Oct 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with advanced cancer that cannot be removed by surgery or have spread to other parts of the body. The purpose of this study is to find the highest and most suitable dose of BI 3968621 that people with advanced cancer can tolerate when taken alone or with ezabenlimab. Another purpose is to find out if taking these medicines can stop tumours from growing or make tumours shrink. In this study, BI 3968621 is given to people for the first time. The study is done in 3 parts. The parts are called Part A, Part A2, and Part B. Participants get BI 3968621 alone or in combination with ezabenlimab depending on which part they are in. Part A is done to find the highest and the most suitable dose of BI 3968621 that people with advanced cancer can tolerate. Part A2 is done to find out if taking BI 3968621, at certain dose levels, can stop or slow down tumour growth in participants with kidney cancer. Part B is done to find out how BI 3968621 is tolerated when given with ezabenlimab. BI 3968621 is taken daily as tablets. Ezabenlimab is given as an infusion into a vein once every 3 weeks. Participants can receive study treatment for up to 2 years if they benefit and can tolerate it. During this time, they visit the study site regularly. The number of visits depends on how participants respond to and tolerate the study treatment. Researchers look at the number of participants with certain severe health problems that happen within 3 weeks after the first study treatment. The study doctors check participants' health, take note of unwanted effects, take blood samples, and check how the cancer responds to study treatment.
Conditions
- Advanced Solid Tumour
Interventions
BI 3968621Drug
BI 3968621
ezabenlimabDrug
ezabenlimab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of dose-limiting toxicities (DLTs) during the primary DLT evaluation period (Dose escalation part A and B)Time frame: During the first treatment cycle, up to 21 days
- Objective response (OR)Time frame: Up to 2 years
Locations
10 sites in 5 countries. Site status is shown where the registry gives one.
Florida Cancer Specialists-Sarasota-61670
Sarasota, Florida · Recruiting
Emory University
Atlanta, Georgia · Not yet recruiting
Thomas Jefferson University
Philadelphia, Pennsylvania · Not yet recruiting
Sarah Cannon Research Institute-Nashville-48456
Nashville, Tennessee · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Not yet recruiting
Universitair Ziekenhuis Gent
Ghent, Belgium · Not yet recruiting
Institut Gustave Roussy
Villejuif, France · Not yet recruiting
Japanese Foundation for Cancer Research
Tokyo, Koto-ku, Japan · Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Spain · Not yet recruiting
Hospital Clinico De Valencia (INCLIVA)
Valencia, Spain · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.